Welcome remarks

sponsored by

Executive spotlight

sponsored by

Has China changed how we build companies?

In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? What still counts as a defensible moat for a company trying to bring a drug to market? And how does it affect how the industry funds and advances programs to bring them to patients?

sponsored by

Investor math versus industrial priority?

If China can advance drugs faster and more cheaply, why should any investor build a biotech (mostly) in the US? We’ll discuss the tension between investors’ desire to bring the best drugs to market as fast as possible versus the US’s industrial and defense priorities.

sponsored by

How pharma thinks about China

As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? We'll dig into what it means for where large drugmakers focus, how they run R&D operations, and other second-order effects that will impact the industry for years to come.

sponsored by